Patent US3886265A successfully refreshed from Google Patents.
← Back to Patent Explorer
US3886265A Expired / Lapsed US ⏱️ 0.0 years remaining

Mouth cleansing preparation

Assignee: Astra Lakemedel AB
•
Filing: 1973-07-02
•
Granted: 1975-05-27
•
Expires: 1993-07-02
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract The use of at least one ene-diol compound having at most 6 carbon atoms and selected from the group consisting of ascorbic acid, isoascorbic acid, dihydroxymaleic acid, dihydroxyfumaric acid, and reductic acid, or salts or derivatives thereof, and an oxidizing agent in the form of a water soluble peroxide selected from the group consisting of alkali metal percarbonate, alkaline earth peroxide, carbamide peroxide, and hydrogen peroxide in the manufacture of preparations effective against bad breath, preferably in the form of peroral dosage units.

Inventors

  • 👤 Hans Christer Arvid Evers
  • 👤 Max Fischler

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-25 21:28
CPC Classifications
A; A61; A61K; A61K8/00; A61K8/18; A61K8/19; A61K8/22; A61K8/30; A61K8/67; A61K8/676; A61K9/00; A61K9/0002; A61K9/0007; A61K9/0012; A61K9/0053; A61K9/0056; A61Q; A61Q11/00

Claims Analysis

Total Claims: 7
Claim 1
Independent Claim 91 words
A COMPOSITION EFFECTIVE IN COMBATING BAD BREATH CONSISTING ESSENTIALY OF AN ENE-DIOL COMPOUND SLECTED FROM THE GROUP CONSISTING OF ASCORBI ACID AND ISOASCOBIC ACID, SAID COMPOUND BEING PERSENT IN AN AMOUNT OF AT LAST 10 MG, AND AN OXIDIZING AGENT IN THE FORM OF A WATER SOLUBLE PEROXIDE SELECTED FROM THE GROUP CONSISTING OF ALKALI METAL PERCARBONATES, ALKALINE EARTH PEROXIDES AND CARBAMIDE PEROXIDE, WHEREIN SAID OXIDIZING AGENT IS PERSENT IN AN AMOUNT CORRESPONDING TO ACTIVE OXYGEN IN AN AMOUNT OF AT LEAST 1 MG, IN EACH CASE PER PERORAL DOSAGE UNIT.
Claim 2
Dependent Claim 91 words
A COMPOSITION EFFECTIVE IN COMBATING BAD BREATH CONSISTING ESSENTIALY OF AN ENE-DIOL COMPOUND SLECTED FROM THE GROUP CONSISTING OF ASCORBI ACID AND ISOASCOBIC ACID, SAID COMPOUND BEING PERSENT IN AN AMOUNT OF AT LAST 10 MG, AND AN OXIDIZING AGENT IN THE FORM OF A WATER SOLUBLE PEROXIDE SELECTED FROM THE GROUP CONSISTING OF ALKALI METAL PERCARBONATES, ALKALINE EARTH PEROXIDES AND CARBAMIDE PEROXIDE, WHEREIN SAID OXIDIZING AGENT IS PERSENT IN AN AMOUNT CORRESPONDING TO ACTIVE OXYGEN IN AN AMOUNT OF AT LEAST 1 MG, IN EACH CASE PER PERORAL DOSAGE UNIT.
Claim 3
Dependent Claim 13 words
A composition according to claim 1 wherein the ene-diol compound is ascorbic acid.
Claim 4
Dependent Claim 51 words
A composition according to claim 1 wherein the ene-diol compound is ascorbic acid present in an amount at least 10 mg and the oxidizing agent is sodium percarbonate present in an amount corresponding to active oxygen in an amount of at least 1 mg, in each case per peroral dosage unit.
Claim 5
Dependent Claim 13 words
A composition according to claim 1, wherein the oxidizing agent is sodium percarbonate.
Claim 6
Independent Claim 84 words
A method of inhibiting bad breath by administering perorally at least 10 mg. of an ene-diol compound selected frOm the group consisting of ascorbic acid, isoascorbic acid, and salts or derivatives thereof, together with an oxidizing agent in the form of a water soluble peroxide selected from the group consisting of alkali metal percarbonates, alkaline earth peroxides, carbamide peroxide, and hydrogen peroxide, in an amount corresponding to active oxygen in an amount of at least 1 mg., in each case per peroral dosage unit.
Claim 7
Independent Claim 84 words
A method of inhibiting bad breath by administering perorally at least 10 mg. of an ene-diol compound selected frOm the group consisting of ascorbic acid, isoascorbic acid, and salts or derivatives thereof, together with an oxidizing agent in the form of a water soluble peroxide selected from the group consisting of alkali metal percarbonates, alkaline earth peroxides, carbamide peroxide, and hydrogen peroxide, in an amount corresponding to active oxygen in an amount of at least 1 mg., in each case per peroral dosage unit.

References Cited (Backward Citations)

US3065139A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1978-05-26 1978-11-25 1979-05-27 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1982-05-26 1982-11-25 1983-05-27 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1986-05-26 1986-11-25 1987-05-27 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag